News
Moderna withdraws FDA filing for flu/COVID combination vaccine, plans resubmission with efficacy data
Moderna filed for FDA approval of its mRNA-1083 combination shot last year. The submission put the biotech on track to win approval in adults aged 50 and older in November 2025. However, at the start of May, Moderna pushed back the expected approval date to 2026 after the FDA asked to see phase 3 efficacy before making a decision on authorization.
Moderna isn’t giving up on the combo shot entirely—it plans to resubmit later this year after it collects more data from its ...
This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
The Trump administration shared the outlines of how it plans to push drug companies to lower their prices in the U.S.
Investor's Business Daily on MSN4d
Moderna Reverses Its Rally As It Faces Another Vaccine SetbackModerna stock toppled Wednesday after the company withdrew its application for a combination Covid and flu vaccine.
Barchart on MSN5d
Moderna Is the Largest Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to InvestIt’s hard to believe Moderna (MRNA)once had a market cap exceeding $204 billion. That was in August 2021 at or near the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback